Marksans Pharma Limited (BOM:524404)
India
· Delayed Price · Currency is INR | Market Cap | 107.58B |
| Revenue (ttm) | 24.74B |
| Net Income (ttm) | 3.68B |
| Shares Out | n/a |
| EPS (ttm) | 8.13 |
| PE Ratio | 29.21 |
| Forward PE | 23.41 |
| Dividend | 0.60 (0.27%) |
| Ex-Dividend Date | Sep 17, 2024 |
| Volume | 70,245 |
| Average Volume | 112,495 |
| Open | 216.15 |
| Previous Close | 226.30 |
| Day's Range | 216.15 - 227.25 |
| 52-Week Range | 130.15 - 358.50 |
| Beta | n/a |
| RSI | 62.07 |
| Earnings Date | May 30, 2025 |
About Marksans Pharma
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin... [Read more]
Financial Performance
In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.
Financial StatementsNews
Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility
Marksans Pharma Limited has announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facilit...
Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets
Marksans Pharma Limited has announced that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets in the U...
Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg
Marksans Pharma Limited saw a 2% surge in its stock price after receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine...
Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg
Marksans Pharma Limited has announced receiving final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. This...
Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ...
Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansion
Marksans Pharma shares jump over 3% on Q2 results
Marksans Pharma Ltd. has announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024, reflecting strong growth in both revenue and prof...
Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY
Marksans Pharma Ltd. reported unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024. Q2 FY25 financial analysis for Marksans Pharma with figure...
Marksans Pharma Q2 FY25 results: Stock surge over 3% ahead of result announcement
Marksans Pharma’s stock saw a significant uptick, jumping over 3% ahead of its Q2 FY25 results. The stock opened at ₹290.70, reaching a high of ₹299.20, and closing near its low of ₹290.65. With a 52-...